Journey Medical earnings release, May 13, 2026

Journey Medical Corp (DERM) · Form 8-K, Item 2.02 · Filed · SEC filing

Journey Medical

Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million

Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026

Cash position increased to $27 million, driven by strong financial performance

Company to hold conference call today at 4:30 p.m. ET

Scottsdale,

AZ – May 13, 2026 – Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,”

“we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2026.

Claude Maraoui,

Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “2026 is off to a strong start, as we delivered solid revenue growth and cash generation in the first quarter of the year. Prescription demand and payer coverage for Emrosi® continue to increase, with the product’s differentiated clinical profile gaining traction as we establish Emrosi® as the best-in-class oral treatment for patients suffering from rosacea. Increasing refill rates and a growing number of Emrosi® prescribers are also building momentum behind the brand. Our net product sales growth in the quarter coupled with disciplined investment in our dermatology-focused commercial infrastructure resulted in improved operating leverage, and we expect this trend to continue going forward. With over $27 million in cash and Emrosi® entering its second year on the market, we remain well-positioned to continue to execute on our strategy and deliver strong financial progress throughout the year.”

Financial Results:

Recent Corporate

Highlights:

Conference Call and Webcast Information

Journey Medical management will conduct a conference call and audio webcast on May 13, 2026, at 4:30 p.m. ET.

To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Journey Medical conference call.

Participants can register for the conference call here: https://dpregister.com/sreg/10209171/10401b25258. Please note that registered participants will receive their dial-in number upon registration.

A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the meeting.

Financial statements

Income Statement

Three-Month Periods Ended — ($ in thousands except for share and per share amounts)

Three-Month Periods Ended – March 31, – 2026Three-Month Periods Ended – March 31, – 2025
Revenue:Product revenue, net15,92113,139
Revenue:Other revenue40
Revenue:Total revenue15,96113,139
Operating expensesCost of goods sold – (excluding amortization of acquired intangible assets)6,2184,790
Operating expensesAmortization of acquired intangible assets1,1261,065
Operating expensesResearch and development39
Operating expensesSelling, general and administrative10,10910,569
Operating expensesTotal operating expenses17,45316,463
Operating expensesLoss from operations-1,492-3,324
Other expense (income)Interest income-157-149
Other expense (income)Interest expense892891
Other expense (income)Foreign exchange transaction losses37
Other expense (income)Total other expense738749
Other expense (income)Loss before income taxes-2,230-4,073
Other expense (income)Net loss-2,230-4,073
Net loss per common share:Basic and diluted-0.08-0.18
Weighted average number of common shares:Basic and diluted27,305,02822,611,040

Balance Sheet

December 31, — ($ in thousands except for share and per share amounts)

March 31, – 2026December 31, – 2025
Current assetsCash and cash equivalents27,21924,090
Current assetsAccounts receivable, net of reserves24,99229,783
Current assetsInventory9,2929,624
Current assetsPrepaid expenses and other current assets3,4643,376
Current assetsTotal current assets64,96766,873
Current assetsIntangible assets, net26,47927,605
Current assetsOperating lease right-of-use asset, net88111
Current assetsTotal assets91,53494,589
Current liabilitiesAccounts payable8,2028,851
Current liabilitiesDue to related party472455
Current liabilitiesAccrued expenses26,10227,567
Current liabilitiesAccrued interest390398
Current liabilitiesIncome taxes payable7070
Current liabilitiesTerm loan, short-term2,500
Current liabilitiesOperating lease liability, short-term94101
Current liabilitiesTotal current liabilities37,83037,442
Current liabilitiesTerm loan, long-term, net of discount22,87325,277
Current liabilitiesOperating lease liability, long-term18
Current liabilitiesTotal liabilities60,70362,737
Stockholders' equityCommon stock, $.0001 par value, 50,000,000 shares authorized, 21,333,946 and 21,144,655 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively22
Stockholders' equityCommon stock - Class A, $.0001 par value, 50,000,000 shares authorized, 6,000,000 shares issued and outstanding as of March 31, 2026 and December 31, 202511
Stockholders' equityAdditional paid-in capital131,516130,307
Stockholders' equityAccumulated deficit-100,688-98,458
Stockholders' equityTotal stockholders' equity30,83131,852
Stockholders' equityTotal liabilities and stockholders' equity91,53494,589
Full release

(1) We define gross margin as total revenue less cost of goods sold divided by total revenue.

About Journey

Medical Corporation

Journey Medical

Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress

Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about

Journey Medical, visit www.journeymedicalcorp.com.

Forward-Looking

Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and

Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “the

Company”, “we”, “us” and “our” may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words “anticipate,” “believe,” “continue,” “estimate,” “may,”

“expect,” “will,” “could,” “project,” “intend,” “potential” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third-party generic competition because their period of exclusivity has ended or they are without patent protection, subjecting them to the potential introduction of new competitor products and/or an increase in market share of existing competitor products, either of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly... (truncated)g to the sale of such products could impair our operating results; competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance on third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of Emrosi® and the successful development, regulatory approval and commercialization of any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity; the substantial doubt expressed about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contact:

Jaclyn Jaffe

(781) 652-4500 ir@jmcderm.com

Media Relations Contact:

Tony Plohoros

6 Degrees

(908) 591-2839 tplohoros@6degreespr.com

JOURNEY

MEDICAL CORPORATION

Unaudited

Condensed Consolidated Balance Sheets

($ in thousands except for share and per share amounts)

JOURNEY

MEDICAL CORPORATION

Unaudited

Condensed Consolidated Statements of Operations

($ in thousands except for share and per share amounts)

Use of Non-GAAP Measures:

In addition to the GAAP financial measures as presented in our Form 10-Q that will be filed with the Securities and Exchange Commission (“SEC”), the Company has, in this press release, included certain non-GAAP measurements, including EBITDA, Adjusted EBITDA, Adjusted EBITDA per share basic and Adjusted

EBITDA per share diluted. We define EBITDA as net income (loss) excluding interest, taxes and depreciation and amortization and we define

Adjusted EBITDA as net income (loss) excluding interest, taxes and depreciation, less certain other non-cash and/or infrequent items not considered to be normal, recurring operating expenses, including, share-based compensation expense, amortization and impairments of acquired intangible assets, inventory step-ups from the purchases of intangibles assets and products, severance, and foreign exchange transaction losses.

In particular, we exclude the following matters for the reasons more fully described below:

Beginning in the first quarter of 2026, we no longer exclude short-term research and development expenses (including any one-time license and milestone payments) from our Non-GAAP Adjusted EBITDA results. Prior period Non-GAAP Adjusted EBITDA results have been revised to reflect this change.

Adjusted EBITDA per share basic and Adjusted EBITDA per share diluted are determined by dividing the resulting Adjusted EBITDA by the number of shares outstanding on an actual and fully diluted basis.

Management believes the use of these non-GAAP measures provides meaningful supplemental information regarding the Company’s performance because (i) they allow for greater transparency with respect to key measures used by management in its financial and operational decision-making,

(ii) they exclude the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company’s core operating performance and that may obscure trends in the Company’s core operating performance and (iii) they are used by institutional investors and the analyst community to help analyze the Company's results. However, Adjusted EBITDA, Adjusted EBITDA per share basic,

Adjusted EBITDA per share diluted and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the

Company and the manner in which they are calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP financial measures used by other companies, including the Company’s competitors.

The table below provides a reconciliation from GAAP to non-GAAP measures:

JOURNEY

MEDICAL CORPORATION

(unaudited)

Reconciliation of GAAP to Non-GAAP Adjusted EBITDA

($ in thousands except for share and per share amounts)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Journey Medical earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.